Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine
News Jun 27, 2011
Reinnervate, has announced that alvetex®, its breakthrough 3D cell culture technology, is among the winners of the prestigious 49th Annual R&D 100 Awards.
Alvetex® is a unique and proprietary cell culture scaffold that, for the first time, enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.
Reinnervate launched its first product, the alvetex® 12-well plate, in Europe at the end of November 2010 and introduced 6-well and 12-well inserts and petri dish formats at the end of March 2011.
The Company intends to launch alvetex® products in a range of other formats over the next 12 months, including 24, 48 and 96 well plates.
Alvetex was chosen by an independent judging panel and the editors of R&D Magazine to be among the 100 most technologically significant products introduced into the marketplace over the past year.
The award will be presented to reinnervate at a special Gala Awards Banquet at the Renaissance Orlando Hotel at SeaWorld in Florida on 13th October 2011.
“The editors were impressed with the strong field of candidates for this year’s R&D 100 Awards. The number and quality of entrants far exceeded that of recent years,” said Rita Peters, editorial director of R&D Magazine.
Professor Stefan Przyborski, reinnervate’s Chief Scientific Officer and founder, commented: “We are extremely proud that alvetex® has been selected as one of this year’s winners of the annual R&D 100 Awards. The team here at reinnervate and at Durham University have shown great dedication in bringing our game-changing alvetex® technology to market and this award goes some way towards recognizing their work. Here at reinnervate we continue to innovate and intend to launch further alvetex® products onto the market over the next 12 months, including a 96-well plate suitable for high-throughput drug screening.”
Since 1963, the R&D 100 Awards have identified revolutionary technologies newly introduced to the market, many of which have become household names.
Winners are picked from industry sectors as diverse as telecommunications, high-energy physics, software, manufacturing, and biotechnology and represent a cross-section of industry, academia, private research firms and government labs.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018